Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Galectin Therapeutics Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Terns Pharmaceuticals (TERN), Sangamo Therapeutics (SGMO) and Gal...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (TERN), Sangamo Therapeutics (SGMO) and Galectin Therapeutics (GALT)

Galectin Therapeutics ( ($GALT) ) has provided an announcement. On March 12, 2026, Galectin Therapeutics appointed internationally recognized neuro...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GALT	$2.23	+1.60%	437.89K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GALT	$2.23	+1.6%	437.89K
3
4
5
6

GALT

GALT

No Data Available

Get Galectin Therapeutics Inc. Data in Excel

Get Galectin Therapeutics Inc. Data in Excel